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Background: Studies have reported that breast cancer (BC) units could increase the quality of care but none has
evaluated the efﬁcacy of alternative options such as private BC networks, which is our study objective.
Patients and methods: We included all 1404 BC patients operated in the public unit or the private network and
recorded at the Geneva Cancer Registry between 2000 and 2005. We compared quality indicators of care between the
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public BC unit and the private BC network by logistic regression and evaluated the effect of surgeon’s afﬁliation on
BC-speciﬁc mortality by the Cox model adjusting for the propensity score.
Results: Both the groups had high care quality scores. For invasive cancer, histological assessment before surgery
and axillary lymph node dissection when indicated were less frequent in the public sector (adjusted odds ratio (OR):
0.4, 95% conﬁdence interval (CI) 0.3–0.7, and OR: 0.4, 95% CI 0.2–0.8, respectively), while radiation therapy after
breast-conserving surgery was more frequent (OR: 2.5, 95% CI 1.4–4.8). Surgeon afﬁliation had no substantial effect
on BC-speciﬁc mortality (adjusted hazard ratio (HR): 0.8, 95% CI 0.5–1.4).
Conclusions: This study suggests that private BC networks could be an alternative to public BC units with both
structures presenting high quality indicators of BC care and similar BC-speciﬁc mortality.
Key words: breast cancer, network, prognosis, quality of care, unit
introduction
Breast cancer (BC) management has dramatically changed in
the last two decades becoming increasingly complex. BC care
requires a comprehensive assessment of multiple tasks needing
a multidisciplinary approach. Professional organizations like
the European Society of Breast Cancer Specialists (EUSOMA)
have issued several recommendations to raise the quality of
care of BC patients [1]. Among those, dedicated BC units with
multidisciplinary pre-therapeutic meetings are proposed to
stimulate professionals to collaborate, to increase their
experience, and to continue professional training. Such units
have been progressively implemented in Europe with the goal
of ensuring high quality standards to all BC patients. In
Switzerland, the Swiss Cancer League with the help of
professional societies is currently developing guidelines for
accreditation of future Swiss BC units [2].
However, the implementation and accreditation of protocols
of such units are quite rigid in structure. Although the
published literature tends to support the efﬁcacy of such BC
units, the level of evidence remains weak [3]. Putative
alternative and more ﬂexible options to BC units, such as BC
networks of health care professionals, have been created but
have never been evaluated in terms of efﬁcacy.
The Swiss canton of Geneva has a particularly high
incidence rate of BC, but survival rates are among the highest
in Europe [4, 5]. The canton of Geneva presents also the best
survival and quality indicators of BC care in Switzerland [6].
Geneva, with its ∼450 000 inhabitants, is essentially urban and
provides dense medical resources. The Swiss health care system
is based on a federal law called LAMal (voted on 18 March
1994) that consists of a basic health insurance that each
individual has to contract. This compulsory insurance covers
for everybody universal access to preventive and therapeutic
care as well as pharmaceuticals. The costs per person are about
350 Euros per month. The Swiss government covers the
complete medical insurance fees for indigent individuals
(∼10% of the population) and part of the fees for people with
low income (∼17% of the population). Approximately 25% of
the population contract supplementary health insurance to
beneﬁt of care not covered by the compulsory health insurance
(i.e. free choice of hospital physicians and superior levels of
hospital accommodation).
Approximately 50% of BC patients are treated in the private
sector. Both the public and private sectors offer an exhaustive
range of care covering screening mammography, diagnostic
magnetic resonance imaging (MRI), positron emission
tomography (PET scan), pathology laboratories to well-
equipped operating rooms.
In the public sector, the public BC unit has established a
systematic multidisciplinary consultation meeting weekly to
discuss the best therapeutic approaches for all new BC cases
referred to the Geneva University Hospitals since 2001. In
addition, all cases are rediscussed after the ﬁrst-line treatments
for the proposition of adjuvant treatments and follow-up.
In the private sector, the BC network SONGe (Séno
ONcologie Genevoise), found in 2000, regroups most of the
private health professionals with particular interest in the ﬁeld
of BC care. This network meets every month to discuss new
topics in BC management in order to reach the highest clinical
standards.
Other private practitioners, who are not afﬁliated to the BC
network, are mostly gynecologists and surgeons who also
operate BC but are not specialized in BC surgery.
The objective of our study is to compare BC quality of care
and outcome between patients operated by surgeons of the
public BC unit and those operated by surgeons of the private
BC network after accounting for the biases linked to patients’
selection. This study was requested by the BC network to
assess the quality of its BC management.
patients and methods
patient, tumor and treatment characteristics
We used data from the Geneva Cancer Registry, which records all incident
cancers occurring in the population of the canton. All hospitals, pathology
laboratories and practitioners are requested to report all cancer cases.
Registrars abstract data from medical and laboratory records. Physicians
regularly receive questionnaires to secure missing data. Recorded data
include sociodemographic variables, tumor characteristics (coded according
to the International Classiﬁcation of Diseases for Oncology ICD-O), stage
at diagnosis (coded according to the TNM Classiﬁcation of Malignant
Tumors), and treatment received within 6 months after diagnosis [7, 8].
The Registry regularly assesses survival. The index date refers to the date
of conﬁrmation of diagnosis or the date of hospitalization if it precedes the
diagnosis and is related to the disease. In addition to passive follow-up
(routine examination of death certiﬁcates and hospital records), active
follow-up is carried out yearly by linking the ﬁles of the Cantonal
Population Ofﬁce in charge of the registration of the resident population
with the Registry database, using a personal identity number.
The exact cause of death is established by systematically consulting
clinical records and/or by inquiring the patient’s physician. The cause of
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death is coded according to the international statistical classiﬁcation of
diseases and health-related problems established by the World Health
Organization [9].
Among the 2075 women diagnosed with a ﬁrst primary BC in 2000–
2005 who have undergone surgery for the ﬁrst treatment, we excluded from
the analysis patients operated outside Geneva (N = 63, 3.0%) or by other
hospital services other than the public BC unit (i.e. thoracic surgery)
(N = 31, 1.5%), and by private surgeon’s not afﬁliated to the private BC
network (N = 577, 28%). The study ﬁnally included 1404 BC patients.
Patients were followed up for survival until 31 December 2009.
Variables of interest included: age (<50, 50–69, 70–79, ≥80 years);
period of diagnosis (2000–2002, 2003–2005); social class coded according
to the last occupation of the woman, and for unemployed, that of the
spouse (high, medium, low, unknown); country of birth (Switzerland,
Southern Europe, other); family history of breast or ovarian cancer (high:
at least one ﬁrst-degree relative diagnosed with breast or ovarian cancer
before the age of 50 years, none: no affected ﬁrst- or second-degree
relative with breast or ovarian cancer, medium: all other known family
histories, unknown); method of discovery (mammography screening,
clinical screening, breast self-examination, other, unknown); stage coded
according to the pathological tumor, node, metastasis (pTNM)
classiﬁcation of malignant tumors (In situ, I, II, III, IV, unknown);
pathological surgical tumor size (in mm); tumor grade (well, moderately,
poorly differentiated, unknown); histology (ductal, lobular, other);
estrogen and progesterone receptor status (positive if ≥10% expressed,
negative, unknown); human epidermal growth factor receptor 2 (HER2)
(positive, negative, unknown); type of surgery (breast-conserving surgery,
mastectomy); number of surgeries (1, >1); surgical margins (positive,
negative, unknown); sentinel lymph node research (yes, no); axillary
lymph node dissection (yes, no); number of lymph nodes removed (<10,
≥10); radiotherapy (yes, no); chemotherapy (yes, no); and hormonal
therapy (yes, no).
surgeon groups
We divided BC patients into two groups according to the surgeon’s
afﬁliation: the public BC unit and the private BC network.
The public BC unit regroups university hospital professionals working
in the ﬁeld of BC care, i.e. gynecologists, medical oncologists, radio
oncologists, plastic surgeons, pathologists, radiologists, social assistants, and
specialized BC nurses. These specialists meet on a weekly basis to discuss
the best therapeutic options for each newly diagnosed BC patient. For the
majority of patients, one meeting is sufﬁcient. If supplementary
investigations are needed, the multidisciplinary team refers the ﬁnal pre-
therapeutic decision to a second meeting. When the patient has undergone
the ﬁrst-line treatments, her ﬁles are reviewed again to propose the best
adjuvant treatment and follow-up.
The private BC network meets monthly to discuss advances in BC
treatment and research. This private network regroups all professionals in
the private sector with particular interest in BC care including
gynecologists, medical oncologists, radio oncologists, plastic surgeons,
pathologists, and radiologists. Afﬁliation to the private BC network has
progressively been strengthened and membership criteria include
experience in BC diagnosis and treatment, participation in international
congresses and/or presentations in national or local congresses in their
ﬁeld. Every 2 years, the network organizes a symposium on the latest
standards for BC guidelines and controversies. Contrary to the public BC
unit, BC patients are not systematically presented to the other members of
the network. Instead, the multidisciplinary work-up is tailored according to
the situation of the patient and left to the appreciation of the ﬁrst specialist
who treated the patient.
indicators of quality of care
We a priori deﬁned state of the art treatment according to the quality
indicators set by the EUSOMA [10]. We selected indicators which could be
determined from our Registry database.
For in situ cancer, we retained the following quality indicators: (i) reporting
of tumor size and grade; (ii) histological assessment before surgery; (iii) a
single operation for the primary tumor (excluding reconstruction); (iv)
negative surgical margin; (v) lack of axillary lymph node dissection; (vi)
breast-conserving surgery for tumor ≤2 cm; and (vii) radiotherapy after
breast-conserving surgery. The last indicator does not appear in the EUSOMA
guidelines but was built on the basis of the last Cochrane review on post-
operative radiotherapy for ductal carcinoma in situ of the breast [11].
For invasive cancer, we considered the following indicators: (i) reporting
of tumor size, grading, and estrogens receptor status; (ii), (iii), and (iv) the
same as for in situ cancer; (v) sentinel lymph node biopsy for clinically
negative axilla; (vi) axillary lymph node dissection when the lymp node is
clinically (physically and/or by imaging) suspect of metastasis or positive
lymph node sentinel biopsy; (vii) at least 10 lymph nodes removed when
axillary dissection was carried out; (viii) breast-conserving surgery for
tumor ≤3 cm; (ix) radiotherapy after breast-conserving surgery if no
metastasis; (x) radiotherapy after mastectomy for pT3 or pT4 or positive
margin or ≥pN2a; (xi) endocrine therapy for estrogen receptor-positive
tumors; and (xii) chemotherapy for estrogen receptor-negative tumors >1
cm or N positive or age ≤35 years. Each indicator was scored 1 when
correctly carried out, 0 otherwise. Indicators were scored only if the item
was applicable to the patient.
We developed one overall score of good practice for in situ using the
seven items and one for invasive cancer using the twelve items. The overall
score obtained by dividing the sum of the values attained at the pertinent
items by the total number of pertinent items multiplied by 100. For
example, in the presence of a patient with a 5 cm in situ tumor with no
mention of tumor grade in the pathological report, with histological
assessment before surgery, with two operations for the primary tumor, with
negative margins, without axillary lymph node dissection, and mastectomy,
the score calculation is as follows: item 1 = 0, item 2 = 1, item 3 = 0,
item 4 = 1, item 5 = 1, item 6 = not pertinent, and item 7 = not pertinent;
the sum is 3, divided by 5 pertinent items = 60%.
statistical analysis
We compared patient and tumor characteristics between the two groups of
surgeons by χ2 test. We also evaluated the differences in the quality of
diagnosis and treatment by logistic regression, considering as cases women
operated by surgeons afﬁliated to the public BC unit, and as controls those
operated by surgeons of the private BC network. We evaluated the effect of
surgeon’s afﬁliation on BC-speciﬁc mortality by Cox models. To account
for the bias related to the selection of patients,, i.e. the nonrandom
assignment to the surgeon’s group, we adjusted all analyses by the
propensity score [12]. To build the propensity score, we identiﬁed by
logistic regression substantial sociodemographic differences between the
surgeon groups and derived a continuous variable which predicted the
individual probability to be treated by one of the two groups.
We considered differences to be statistically signiﬁcant at P value <0.05
and used SPSS software (Version 14; SPSS Inc, Chicago, IL, USA).
results
patient, and tumor characteristics according to
surgeon’s afﬁliation
Of the 1404 patients, 166 had in situ and 1238 invasive BC.
Surgeons of the public BC unit operated 50% (N = 83) of the
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in situ cancer patients and 60.7% (N = 752) of the patients with
invasive tumors. Patient and tumor characteristics are
presented in Table 1 for in situ cancer and Table 2 for invasive
cancer. For in situ cancer, when compared with women
operated in the private BC network, women operated by a
surgeon of the public BC unit were of lower social class, had
less frequently tumor detected by mammography screening,
had more often a report on tumor grade, and presented more
frequently a tumor with non-ductal histology (Table 1). In the
logistic regression model, two variables,, i.e. period of diagnosis
and social class, were retained by the logistic regression model
to build the propensity score.
For invasive cancer, patients treated by surgeons from the
public BC unit were older, of lower social class, were more
often born in Southern Europe, and had less often tumor
detected by screening. For other remaining variables such as
familial history, tumor characteristics (including stage,
hormone receptor status, and grade), there were no differences
among the surgeon groups. In fact, the only substantial
difference was the lower proportion of unknown data for
patients treated by public BC unit surgeons compared with
those treated by surgeons of the private BC network (Table 2).
In the logistic regression model, the propensity score was built
on age, country of birth, and social class.
score of quality of care according to surgeon’s
afﬁliation
Tables 3 and 4 show the distribution of quality indicators
between the two surgeon groups for in situ and invasive
cancer, respectively. The tables also present the P values of the
χ2 tests and the odds ratios (OR) derived from the logistic
regression adjusted for the propensity scores (right columns).
For in situ cancer, the mean score of care quality (based on
the seven relevant items) was high in each group: 82% for the
public BC unit and 78% for the private BC network (P =
0.132). Only two indicators were substantially different
between the public BC unit and the private BC network.
Higher report of in situ tumor size and grading was observed
for women operated by the public BC unit surgeons [69%
versus 42%, OR adjusted for the propensity score for the public
BC unit versus private BC network: 3.0, 95% conﬁdence
interval (CI): 1.5–5.8, P = 0.001]. Conversely, the public BC
unit surgeons carried out less frequently breast-conserving
surgery when indicated than surgeons in the private BC
network (65% versus 90%, OR: 0.3, 95% CI 0.1–0.9, P = 0.030).
We observed no differences for other indicators.
For invasive cancer, the mean score of quality (based on
twelve items) was high with a slight but signiﬁcant difference
in favor of patients treated by the surgeons of the private BC
network (85% for the public BC unit and 87% for the private
BC network; P = 0.007). Signiﬁcant differences existed between
the two groups concerning the histological assessment before
surgery, which was not reported in 13% of the public BC unit
patient ﬁles compared with only 6% in the private BC network
(OR: 0.4, 95% CI 0.3–0.7, P < 0.000). The use of axillary lymph
node dissection when indicated was lower in the public BC
unit than in the private BC network (85% versus 94%, OR: 0.4,
95% CI 0.2–0.8, P = 0.018). Radiation therapy after breast-
conserving surgery was more frequently carried out for
patients operated by the public BC unit surgeons than those
operated by the private BC network surgeons (96% versus 93%,
OR: 2.5, 95% CI 1.3–4.8, P = 0.004). The use of tamoxifen,
when indicated, tended to be more frequent in the public BC
unit than in the private BC network. The opposite was
observed for the use of chemotherapy. However, the last two
results were not signiﬁcant in adjusted analysis.
breast cancer BC-speciﬁc mortality according
to surgeon’s afﬁliation
The mean follow-up of patients with invasive cancer was 6.3
years and 67 women died from BC during the study follow-up.
Table 5 presents the effect of surgeon’s afﬁliation on BC-
speciﬁc mortality among patients with invasive BC. Hazard
ratios (HRs) were adjusted for propensity scores. The surgeon’s
afﬁliation had no substantial effect on BC-speciﬁc mortality
(adjusted HR for women operated by surgeons of the BC
network when compared with those operated by surgeons of
the public BC unit: 0.8, 95% CI 0.5–1.4). Additional
adjustment for tumor characteristics (including stage, grade,
and tumor receptors) did not modify the result.
discussion
Although there is some scientiﬁc evidence that dedicated BC
units with multidisciplinary tumor boards increases the quality
of care, we have no data evaluating the effectiveness of other
approaches [13]. We evaluated whether the quality of care
differed between patients treated by surgeons afﬁliated to the
public BC unit and those treated by surgeon members of the
private BC network, accounting for patient’s selection bias to
provide interpretable comparison. We found that the quality of
care of the two approaches is high and very close.
Furthermore, BC-speciﬁc mortality is similar between the two
surgeon groups.
For in situ cancer, differences in quality indicators between
the public BC unit and the private BC network were mainly
linked to the higher report rate of in situ tumor size and
grading for women operated in the public BC unit. This result
is due to coding differences between pathologists at the Geneva
University Hospitals and those of the private sector. The latter
frequently describe cancer grade as ‘low/medium’ or ‘medium/
high’, making it difﬁcult for registrars to recode data according
to the three levels (low, medium, and high) grading
classiﬁcation of disease in oncology used by cancer registries.
On the contrary, for women with small tumors, the public BC
unit surgeons tended to perform breast-conserving surgery less
frequently than surgeons of the private BC network.
For invasive cancer, the histological assessment before
surgery was less frequently carried out for patients operated by
the public BC unit surgeons, with ∼10% of women operated
on the basis of cytological evaluation only. Axillary dissection,
when indicated, was less frequently carried out by surgeons
from the public BC unit, with approximately one-third of the
patients not having dissection. On the contrary, radiation
therapy after breast-conserving surgery was less frequently
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Table 1. Patient, tumor, and treatment characteristics according to surgeon’s afﬁliation among patients with in situ breast cancer
Surgeon’s afﬁliation P value for
heterogeneity testaPublic BC unit
[N (%); 83 (50.0)]
Private BC network
[N (%); 83 (50.0)]
Mean age at diagnosis (years) 57.5 57.3 0.942
Age 0.238
<50 21 (25.3) 15 (18.1)
50–69 48 (57.8) 60 (72.3)
70–79 11 (13.3) 7 (8.4)
≥80 3 (3.6) 1 (1.2)
Period of diagnosis
2000–2002 44 (53.0) 32 (38.6) 0.086
2003–2005 39 (47.0) 51 (61.4)
Social class
High 16 (20.3) 23 (28.0) 0.004
Medium 47 (59.5) 56 (68.3)
Low 16 (20.3) 3 (3.7)
Unknown 4 (–) 1 (–)
Country of birth
Switzerland 42 (50.6) 47 (56.6) 0.059
Southern Europe 23 (27.7) 11 (13.3)
Other 18 (21.7) 25 (30.1)
Method of detection
Mammography screening 57 (68.7) 67 (82.7) 0.005
Clinical screening 1 (1.2) 3 (3.7)
Breast self-palpation 5 (6.0) 7 (8.6)
Other 20 (24.1) 4 (4.9)
Unknown — 2 (–)
Familial history of BC
High 9 (10.8) 9 (11.5) 0.808
Medium 16 (19.3) 12 (15.4)
None 58 (69.9) 57 (73.1)
Unknown — 5 (–)
Grade
Well differentiated 15 (20.5) 9 (22.0) 0.999
Other 58 (79.5) 32 (78.0)
Unknown 10 (–) 42 (–)
Histology
Ductal 77 (92.8) 83 (100.0) 0.044
Lobular 5 (6.0) —
Other 1 (1.2) —
Estrogen receptor status
Positive 66 (89.2) 59 (79.7) 0.173
Negative 8 (10.8) 15 (20.3)
Unknown 9 (–) 9 (1–)
Progesterone receptor status
Positive 53 (71.6) 41 (55.4) 0.060
Negative 21 (28.4) 33 (44.6)
Unknown 9 (–) 9 (–)
Her2 receptor statusb
Positive 9 (64.3) 3 (42.9) 0.397
Negative 5 (35.7) 4 (57.1)
Unknown 69 (–) 76 (–)
aAfter exclusion of unknown data.
bSince 2001.
BC, breast cancer; HER2, human epidermal growth factor receptor 2.
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Table 2. Patient, tumor, and treatment characteristics according to surgeon’s afﬁliation among patients with invasive breast cancer
Surgeon’s afﬁliation P value for
heterogeneity testa
Public BC unit
[N (%); 752 (60.7)]
Private BC network
[N (%); 486 (39.3)]
Mean age at diagnosis (years) 61.8 58.8 <0.001
Age
<50 141 (18.8) 101 (20.8) <0.001
50–69 394 (52.4) 306 (63.0)
70–79 150 (19.9) 61 (12.6)
≥80 67 (8.9) 18 (3.7)
Period of diagnosis
2000–2002 350 (46.5) 237 (48.8) 0.449
2003–2005 402 (53.5) 249 (51.2)
Social class
High 90 (12.3) 137 (28.8) <0.001
Medium 427 (58.3) 295 (62.1)
Low 215 (29.4) 43 (9.1)
Unknown 20 (–) 11 (–)
Country of birth
Switzerland 362 (48.1) 254 (52.3) <0.001
Southern Europe 258 (34.3) 96 (19.8)
Other 132 (17.6) 136 (28.0)
Method of detection
Mammography screening 290 (38.6) 201 (42.1) 0.016
Clinical screening 67 (8.9) 63 (13.2)
Breast self-palpation 288 (38.3) 163 (34.2)
Other 106 (14.1) 50 (10.5)
Unknown 1 (–) 9 (–)
Familial history of BC
High 68 (9.1) 31 (6.8) 0.125
Medium 173 (23.2) 126 (27.5)
None 505 (67.7) 302 (65.8)
Unknown 6 (–) 27 (–)
Stage
I 389 (52.2) 236 (50.3) 0.475
II 301 (40.4) 206 (43.9)
III 51 (6.8) 24 (5.1)
IV 4 (0.5) 3 (0.6)
Unknown 7 (–) 17 (–)
Lymph node invasion
No 517 (69.1) 317 (67.7) 0.612
Yes 231 (30.9) 151 (32.3)
Unknown 4 (–) 18 (–)
Grade
Well differentiated 250 (34.1) 161 (33.8) 0.950
Other 404 (65.9) 220 (66.2)
Unknown 18 (–) 9 (–)
Histology
Ductal 612 (81.4) 399 (82.1) 0.853
Lobular 109 (14.5) 70 (14.4)
Other 31 (4.1) 17 (3.5)
Estrogen receptor status
Positive 652 (86.8) 429 (89.6) 0.179
Negative 99 (13.2) 50 (10.4)
Unknown 1 (–) 7 (–)
Progesterone receptor status
Positive 552 (73.5) 354 (73.9) 0.895
Negative 199 (26.5) 125 (26.1)
Unknown 1 (–) 7 (–)
Continued
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delivered to patients treated in the private BC network than in
the public BC unit.
Reviews on the effect of multidisciplinary care on BC
survival in particular, or more generally on all types of cancers
conclude that although intrinsically multidisciplinary care
should be associated with better survival, there is little evidence
to support this [3, 14]. Great disparities exist in study designs
and in the deﬁnition of multidisciplinary approaches. This also
applies for studies on BC units. Some studies have considered
the specialization, others the membership of a professional
society (association), the afﬁliation to a specialized center, the
hospital or the surgeon’s caseload. One cohort study on almost
30 000 operated BC patients in the Los Angeles County has
reported that treatment by a surgical oncologist compared with
Table 2. Continued
Surgeon’s afﬁliation P value for
heterogeneity testa
Public BC unit
[N (%); 752 (60.7)]
Private BC network
[N (%); 486 (39.3)]
HER2 receptorsb
Positive 135 (24.8) 65 (25.4) 0.861
Negative 409 (75.2) 191 (74.6)
Unknown 208 (–) 230 (–)
aAfter exclusion of unknown data.
bRecorded since 2001.
BC, breast cancer; HER2, human epidermal growth factor receptor 2.
Table 3. Quality of diagnosis assessment and treatment according to surgeon’s afﬁliation among patients with in situ breast cancer
Indicator of quality Public BC unit
[N (%); 83 (50.0)]
Private BC network
[N (%); 83 (50.0)]
P value for
heterogeneity
Propensity score adjusted
odds ratio (OR) comparing
public unit versus
private network OR (95% CI)
P value of logistic
regression
Reporting of tumor size and grading
Yes 57 (68.7) 35 (42.2) 0.001 1 (reference) 0.001
No 26 (31.3) 48 (57.8) 3.0 (1.5–5.8)
Histological assessment before surgery
Yes 69 (83.1) 62 (74.7) 0.253 1 (reference) 0.170
No 14 (16.9) 21 (25.3) 1.8 (0.8–3.9)
Number of interventions
One 71 (85.5) 66 (79.5) 0.414 1 (reference) 0.607
More 12 (14.5) 17 (20.5) 1.3 (0.5–2.9)
Surgical margins
Negative 77 (93.9) 80 (96.4) 0.496 1 (reference) 0.359
Positive 5 (6.1) 3 (3.6) 0.5 (0.1–2.3)
Unknown 1 (–) —
Axillary dissection
No 73 (88.0) 75 (90.4) 0.804 1 (reference) 0.842
Yes 10 (12.0) 8 (9.6) 1.1 (0.4–3.3)
Breast-conserving surgery for tumor ≤20 mm
Yes 32 (65.3) 44 (89.8) 0.007 1 (reference) 0.030
No 17 (34.3) 5 (10.2) 0.3 (0.1–0.9)
>20 mm or NOS not requested 34 (–) 34 (–)
Radiotherapy after breast-conserving surgery
Yes 41 (89.1) 54 (83.1) 0.423 1 (reference) 0.413
No 5 (10.9) 11 (16.9) 1.6 (0.5–5.2)
Not pertinent (mastectomy) 37 (–) 18 (–)
Score of care quality
≤75% 60 (72.3) 46 (55.4) 0.035 1 (reference)
>75% 23 (27.7) 37 (44.6) 2.3 (1.1–4.5) 0.021
Mean score of quality 81.7 77.8 0.132
BC, breast cancer.
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Table 4. Quality of diagnosis assessment and treatment according to surgeon’s afﬁliation among patients with invasive breast cancer
Indicator of quality Public BC unit
[N (%); 752 (60.7)]
Private BC network
[N (%); 486 (39.3)]
P value for heterogeneity Propensity score adjusted
odds ratio (OR) comparing public
unit versus private network
OR (95% CI)
P value of logistic
regression
Reporting of hormone receptor, tumor size, and grading
Yes 719 (95.6) 470 (96.7) 0.373 1 (reference) 0.351
No 33 (4.4) 16 (3.3) 0.7 (0.4–1.4)
Histological assessment before surgery
Yes 652 (86.7) 456 (93.8) <0.001 1 (reference) <0.001
No 100 (13.3) 30 (6.2) 0.4 (0.3–0.7)
Number of interventions
One 651 (86.6) 401 (82.5) 0.061 1 (reference) 0.148
More 101 (13.4) 85 (17.5) 1.3 (0.9–1.8)
Surgical margins
Negative 679 (90.9) 455 (93.8) 1 (reference)
Positive 68 (9.1) 30 (6.2) 0.068 0.7 (0.4–1.1) 0.080
Unknown 5 (–) 1 (–) excluded
Sentinel lymph node if indicateda
Yes 368 (69.7) 254 (73.2) 0.286 1 (reference) 0.679
No 160 (30.3) 93 (26.8) 0.9 (0.7–1.3)
Not pertinent 224 (–) 139 (–) excluded
Axillary dissection when indicateda
Yes 187 (85.4) 127 (94.1) 0.015 1 (reference) 0.018
No 32 (14.6) 8 (5.9) 0.4 (0.2–0.8)
Not pertinent 533 (–) 351 (–) excluded
Number of lymph nodes removed
≥10 281 (75.9) 186 (75.0) 0.849 1 (reference) 0.798
<10 89 (24.1) 62 (25.0) 1.1 (0.7–1.6)
Not pertinent 382 (–) 238 (–) excluded
Breast-conserving surgery when indicateda
Yes 518 (79.2) 366 (84.3) 0.039 1 (reference) 0.105
No 136 (20.8) 68 (15.7) 0.8 (0.5–1.1)
Not pertinent 98 (–) 52 (–) excluded
Breast-conserving surgery and radiotherapy
Yes 534 (96.4) 353 (92.9) 0.022 1 (reference) 0.004
No 20 (3.6) 27 (7.1) 2.5 (1.4–4.8)
Not pertinent 198 (–) 106 (–) excluded
Mastectomy and radiotherapy when indicateda
Yes 11 (44.0) 7 (70.0) 0.264 1 (reference) 0.314
No 14 (56.0) 3 (30.0) 0.4 (0.1–2.2)
Not pertinent 727 (–) 476 (–) excluded
Anti-estrogen use when indicateda
Yes 611 (93.7) 390 (90.9) 0.096 1 (reference) 0.084
No 41 (6.3) 39 (9.1) 1.5 (0.9–2.5)
Not pertinent 100 (–) 57 (–) excluded
Chemotherapy use when indicateda
Yes 164 (56.0) 131 (72.0) <0.001 1 (reference) 0.082
No 129 (44.0) 51 (28.0) 0.7 (0.5–1.1)
Not pertinent 459 (–) 304 (–) excluded
Score of care quality
<50% 24 (3.2) 15 (3.1) 0.030
<75% 172 (22.9) 86 (17.7)
<90% 291 (38.7) 176 (36.2)
>90–100% 265 (35.2) 209 (43.0)
Score of care quality
≤75% 196 (26.1) 101 (20.8) 0.035 1 (reference) 0.220
>75% 556 (73.9) 385 (79.2) 0.8 (0.6–1.1)
Mean score of care quality 85.0 87.3 0.007
aSee the patients and methods section.
BC, breast cancer.
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a non-specialist surgeon resulted in a 33% reduction in the risk
of death at 5 years in multivariate analysis, while treatment at a
specialist center did not affect survival [15]. A signiﬁcant
increase in survival was also observed in a population-based
cohort of 2192 patients in Oklahoma city for patients operated
by specialist surgeons versus non-specialists. This study also
reported differences in the use of adjuvant therapy, type of
surgery, and compliance to treatment between specialized and
non-specialized surgeons [16]. In Scotland, a retrospective
study of 3786 patients reported a 16% of decreased mortality
after adjustment for age, tumor size, socioeconomic status, and
nodal involvement in BC patients cared for by specialist
surgeons [17]. Another study including 24 834 patients from
the Florida Cancer Data System reported higher survival rates
for patients treated at teaching hospitals compared with
community or low-volume hospitals [18, 19]. The authors
concluded that many of these differences were due to the
decreased use of proven adjuvant therapies, underlining the
need for an integrated treatment for this disease. In Norway,
where nearly all BC patients are treated in public hospitals,
breast units with multidisciplinary meetings have been
introduced in a staggered fashion along with a screening
program since 1996. A cohort study of 1131 patients with
resectable BC reported that relapse-free survival and overall
survival did not differ substantially between the hospital groups
based on the surgical workload or between university and non-
university hospitals [20].
As previously reported, the quality of BC care is high in
Switzerland [21]. This study reported that multidisciplinary
therapeutic discussion was associated with substantially higher
average quality of care, higher surgical sub-score and higher
nonsurgical sub-score. The article also shows that BC patients
treated in the canton of Geneva had the highest mean and
surgical quality of care scores. The high degree of compliance
with BC care recommendations found in the canton of Geneva
was remarkable. As possible explanation, the authors of the
study evoked the fact that in Geneva, most of the predictors of
high management score are present: high caseload and clinical
research at the Geneva University Hospitals, together with a
higher proportion of patients with tertiary education, income
in the highest tertile, and living in an urban area with high
accessibility to specialized care. Our study results showing high
scores for both the public BC unit and the private BC network
contribute to explain the overall good performance observed in
Geneva.
In our study, we found few differences in the quality of care
and no differences in survival between the public BC unit and
the private BC network. This could be linked to the fact that
sophisticated medical tools are widely available in the public as
well as in the private sector. Such tools include mammography,
ultrasound, MRI, PET scan, good operating theaters with
experienced pathologists in BC in both sectors of care. As seen
at the Geneva University Hospitals, numerous private
oncologists and gynecologists in the canton working as breast
surgeons attend international breast conferences, meet
regularly to update their knowledge, and discuss patient’s
medical ﬁles. Another particularity of the medical system in
Geneva is that nearly 50% of the cancer patients are treated in
the private sector. A total of 1981 BC patients were operated in
the canton during the study period. Among those, 1146 (58%)
were operated by private surgeons (i.e. 569, 29% by those
afﬁliated to the BC network and 577, 29% by other private
surgeons), a situation very different from other parts in the
world [22].
As expected, our study shows that the public BC unit,
considered as the reference for the public sector in the canton,
served more disadvantaged patients with higher proportions of
elderly, low social class, and foreign patients. Despite that, the
quality of care of the public BC unit remains high. On the
other hand, the added value for a patient to remain within her
doctor’s caring referees, as it is probably more often the case in
the private BC network. This, although not easily computable,
could be important for many patients [23].
The main limitations of our study are linked to its
observational nature, as it is the case of all previous studies
because of the lack of clinical trials testing BC units or network
efﬁcacy. In our study, patients treated by the public BC unit
and the private BC network are not similar in terms of age,
social class, and nationality. These sociodemographic variables,
in particular age and social class, can strongly affect BC quality
of care and outcome [24, 25]. To minimize the selection bias
of BC patients’ recruitment between surgeons groups, we
adjusted all analyses for the propensity score. This has never
been carried out before. We cannot, however, exclude the
residual selection effect from unrecorded variables, such as
patient co-morbidities, or other factors linked to the patient’s
status, social context, or behavior. Analysis by age sub-groups
(<50, 50–70, ≥71 years), to indirectly account for the
increasing presence of co-morbidities with advancing age, did
not change the results presented on the quality scores but only
on the levels of signiﬁcance due to the lowered power. Also,
the results from survival analysis should be considered as
preliminary because of the short follow-up and the few events
(i.e. cancer deaths) linked to high BC survival. Also, the
deﬁnitions we use for our BC unit and network correspond to
speciﬁc daily practice of BC care in the canton of Geneva, the
public BC unit has not yet been formally accredited as deﬁned
by the EUSOMA ‘Requirements of a specialist breast unit
2010’. This unit responds to most, but not all, necessary
criteria issued. It includes all BC specialists, an important
caseload, a weekly multidisciplinary medical pre-therapeutic
and post-operative discussion of nearly all newly diagnosed
patients in the public sector, and centralized medical facilities
including speciﬁc radio-diagnostic and radiotherapy. The
private BC network’s work is more informal with no pre-
therapeutic systematic discussion and medical facilities are not
centralized in one institution. Therefore, the results presented
in our study could not be easily extrapolated in other contexts.
Table 5. Effect of surgeon’s afﬁliation on breast cancer speciﬁc mortality
Surgeon’s afﬁliation Crude hazard ratio
(HR; 95% CI)
HR adjusted for
propensity scores (95% CI)
Public BC unit 1 (reference) 1 (reference)
Private BC network 0.7 (0.4–1.2) 0.8 (0.5–1.4)
BC, breast cancer.
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Also, the way of collecting data on treatments between the
public and private sectors differed with direct access to hospital
ﬁles for the public sector and through speciﬁc questionnaires
for the private sector. However, this could inﬂuence the
recording of later use of adjuvant treatments but not surgery or
radiotherapy, as the registry recorded similarly and directly the
data from pathological and radiotherapy reports from both the
sectors. Finally, this study did not consider the costs or the
patient’s satisfaction which are important indicators of the care
system evaluation.
The strength of our study is the use the quality indicators of
care developed speciﬁcally for accreditation of BC units by
EUSOMA, which will allow future comparisons with other
studies [10]. We are, however, aware of the fact that these
indicators are not all linked to prognosis (such as use of breast-
conserving surgery for small tumors) but are more linked to
the quality of life. We could not study all the recommended
indicators, including those concerning the evaluation of over-
treatment or breast reconstruction, because part of the
information needed to construct such indicators was lacking
during the time of this study. Another strength of our study is
the determination of exact cause of death by trained registrars
from medical ﬁles and inquiries to physicians which offer a
unique opportunity to assess correctly true BC-speciﬁc
mortality.
In conclusion, in Geneva, the quality of BC care is high in
both the public BC unit and the private BC network. Similarly
operating networks could be considered as a less stringent
alternative of BC units after careful evaluation of their efﬁcacy.
Finally, despite high quality of care, there is still rule for both
improvement and homogenization of BC treatment between
the private and public sectors.
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